Focus on medical product safety is at its prime in the US and Europe. Numerous safety initiatives have been launched in both regions over the past few years and healthcare stakeholders are now turning towards regulators and thought leaders to determine what the immediate and residual effects will be. However, several key themes on what will be needed to improve product safety have emerged from the initiatives already.

The shift towards evidence-based medicine is a welcome development, with companies already using innovative approaches to support more robust decision-making, writes Dr Richard Gliklich. Fail to address some of the industry's outdated silo structures, however, and some stakeholders will be left wanting.

Numerous initiatives in the US and Europe show that the focus on medical product safety is at its prime. All healthcare stakeholders are looking towards regulators and thought leaders to determine what the immediate and residual effects will be, writes Dr Richard Gliklich